β-Amyloid Antibodies

Santa Cruz Biotechnology features a diverse variety of β-Amyloid monoclonal antibodies for research in understanding β-amyloid's role in neurodegenerative diseases, particularly Alzheimer's disease. β-Amyloid monoclonal antibodies are compatible with multiple techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). β-Amyloid is a peptide that aggregates to form plaques in the brains of Alzheimer's patients, contributing to neurodegeneration and cognitive decline. The study of β-amyloid is crucial for elucidating the mechanisms of Alzheimer's disease and developing potential therapeutic strategies. Understanding the dynamics of β-amyloid accumulation and clearance can provide insights into disease progression and inform clinical approaches. β-Amyloid research continues to reveal new pathways and mechanisms involved in neurodegeneration. Investigating β-amyloid formation and aggregation patterns helps researchers better understand the timeline of disease onset and progression. Current research focuses on identifying key interaction partners and signaling cascades associated with β-amyloid accumulation. Santa Cruz Biotechnology monoclonal antibodies for β-Amyloid research support scientists worldwide in their mission to uncover new treatments for Alzheimer's disease.